SCHEMBL3294243

SCHEMBL3294243

Cc1snc(-c2ccc(O)cc2)c1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 6/20 0.43
GRM1 Q13255 1/20 0.43
ALDH1A1 P00352 1/20 0.39
PDGFRB P09619 1/20 0.39
KDR P35968 1/20 0.39
RARA P10276 1/20 0.37
RARB P10826 1/20 0.37
RARG P13631 1/20 0.37
BACE1 P56817 1/20 0.37
PLTP P55058 1/20 0.36
TSHR P16473 1/20 0.36
PDE10A Q9Y233 1/20 0.36
MAPK1 P28482 1/20 0.36
MAP2K4 P45985 1/20 0.36
MAPKAPK2 P49137 1/20 0.36
MAPKAPK3 Q16644 1/20 0.36
MAPK6 Q16659 1/20 0.36
MAPKAPK5 Q8IW41 1/20 0.36
KMT2A Q03164 3/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12691935 0.88 KDR (0.49) DHODHALDH1A1PDGFRBKDRRARA
SCHEMBL11789345 0.86 PDE10A (0.49) DHODHGRM1ALDH1A1RARARARB
SCHEMBL6143587 0.85 DHODH (0.47) DHODHGRM1BACE1KMT2AMAPT
SCHEMBL899644 0.83 BACE1 (0.52) GRM1ALDH1A1BACE1MAPT
SCHEMBL14710197 0.80 DGAT1 (0.51) KDRBACE1TSHR
SCHEMBL14710914 0.77 LPAR1 (0.40)
SCHEMBL14710182 0.76 BACE1 (0.42) ALDH1A1BACE1
SCHEMBL14710959 0.73 HRH3 (0.37) GRM1PDGFRBKDRBACE1
SCHEMBL11790564 0.71 ALDH1A1 (0.47) DHODHALDH1A1TSHRKMT2AMAPT
SCHEMBL3401735 0.71 PTGS1 (0.52) DHODHALDH1A1KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732434-B2 Macrocyclic acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-08 US disclosed
US-7732434-B2 Macrocyclic acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-08 US disclosed
US-7732434-B2 Macrocyclic acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-06-08 US disclosed
US-20080262055-A1 Macrocyclic Acyl Guanidines as Beta-Secretase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-10-23 US disclosed
US-20080262055-A1 Macrocyclic Acyl Guanidines as Beta-Secretase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-10-23 US disclosed
US-20080262055-A1 Macrocyclic Acyl Guanidines as Beta-Secretase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262055-A1 Macrocyclic Acyl Guanidines as Beta-Secretase Inhibitors BACE1, APP, BACE2 DHODH 3281/4885GRM1 145/4885ALDH1A1 2834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.